44 institutions hold shares in 9 Meters Biopharma Inc. (NMTR), with 27.51M shares held by insiders accounting for 12.73% while institutional investors hold 24.25% of the company’s shares. The shares outstanding are 216.07M, and float is at 175.27M with Short Float at 2.12%. Institutions hold 21.17% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Orbimed Advisors LLC. with over 25.72 million shares valued at $22.09 million. The investor’s holdings represent 11.90% of the NMTR Shares outstanding. As of Dec 30, 2020, the second largest holder is Adage Capital Partners GP L.L.C. with 13.0 million shares valued at $11.17 million to account for 6.02% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 7.19 million shares representing 3.33% and valued at over $6.18 million, while AIGH Capital Management LLC holds 1.44% of the shares totaling 3.12 million with a market value of $2.68 million.
9 Meters Biopharma Inc. (NASDAQ: NMTR) is 53.67% higher on its value in year-to-date trading and has touched a low of $0.41 and a high of $2.26 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NMTR stock was last observed hovering at around $1.42 in the last trading session, with the day’s loss setting it -0.1% off its average median price target of $5.50 for the next 12 months. It is also 78.0% off the consensus price target high of $6.00 offered by 5 analysts, but current levels are 56.0% higher than the price target low of $3.00 for the same period.
Currently trading at $1.32, the stock is -16.96% and -17.35% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.52 million and changing -7.04% at the moment leaves the stock 38.92% off its SMA200. NMTR registered 180.85% gain for a year compared to 6-month gain of 72.64%. The firm has a 50-day simple moving average (SMA 50) of $1.7037 and a 200-day simple moving average (SMA200) of $1.1280.
The stock witnessed a -20.48% loss in the last 1 month and extending the period to 3 months gives it a 48.82%, and is -25.00% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.13% over the week and 10.80% over the month.
Distance from 52-week low is 221.87% and -41.59% from its 52-week high.
9 Meters Biopharma Inc. (NMTR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for 9 Meters Biopharma Inc. (NMTR) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
9 Meters Biopharma Inc. is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at -$0.03.The EPS is expected to grow by 28.30% this year.
9 Meters Biopharma Inc. (NMTR) Insider Activity
A total of 8 insider transactions have happened at 9 Meters Biopharma Inc. (NMTR) in the last six months, with sales accounting for 0 and purchases happening 8 times. The most recent transaction is an insider purchase by Sirgo Mark A, the company’s Director. SEC filings show that Sirgo Mark A bought 230,769 shares of the company’s common stock on Dec 15 at a price of $0.65 per share for a total of $0.15 million. Following the purchase, the insider now owns 0.77 million shares.
9 Meters Biopharma Inc. disclosed in a document filed with the SEC on Dec 15 that Temperato John (Chief Executive Officer) bought a total of 153,846 shares of the company’s common stock. The trade occurred on Dec 15 and was made at $0.65 per share for $100000.0. Following the transaction, the insider now directly holds 0.98 million shares of the NMTR stock.
Still, SEC filings show that on Dec 15, Sitar Edward J (Chief Financial Officer) acquired 61,538 shares at an average price of $0.65 for $40000.0. The insider now directly holds 129,338 shares of 9 Meters Biopharma Inc. (NMTR).